MCP
SABS icon

Miller Capital Partners’s SAB Biotherapeutics SABS Stock Holding History

Miller Capital Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2K Hold
12,870
– – 0.02% 173
2026
Q1 		$49.3K Buy
+12,870
New +$51.3K 0.02% 166

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Miller Capital Partners's SABS Position: Q2 2026 in Review

Miller Capital Partners held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 12,870 shares worth $50.2K. The position accounts for 0.02% of the portfolio, ranked #173.

Miller Capital Partners first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Miller Capital Partners held 12,870 shares of SAB Biotherapeutics worth $50.2K as of Q2 2026.
  • Miller Capital Partners left its SAB Biotherapeutics share count unchanged in Q2 2026.
  • SAB Biotherapeutics made up 0.02% of Miller Capital Partners's portfolio in Q2 2026, its #173 holding.
  • Miller Capital Partners first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Miller Capital Partners's 13F filing for Q2 2026, filed 12 Aug 2026.